Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine is a unique sedative medication able to provide sedation without causing
respiratory depression and maintaining neurological functions. Patients having an acute
ischemic stroke and need to undergo endovascular therapy require constant assessment of their
neurological status prior, during and after the interventional procedure. In this study the
investigators will compare the efficacy of Dexmedetomidine to other standard sedative
medications in providing optimal sedative effect while maintaining neurological function.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer